Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy

被引：9

作者：

Morimoto, Masahiro ^{[1
]}

Nishino, Kazumi ^{[2
]}

Wada, Kentaro ^{[1
]}

Imamura, Fumio ^{[2
]}

Konishi, Koji ^{[1
]}

Kuhara, Hanako ^{[2
]}

Tamiya, Motohiro ^{[2
]}

Inoue, Takako ^{[2
]}

Kunimasa, Kei ^{[2
]}

Kimura, Madoka ^{[2
]}

Hirata, Takero ^{[3
,4
]}

Kanayama, Naoyuki ^{[1
]}

Toratani, Masayasu ^{[1
]}

Kawachi, Hayato ^{[2
]}

Ohira, Kika ^{[2
]}

Nakanishi, Erina ^{[1
,4
]}

Ohira, Shingo ^{[1
]}

Sagawa, Tomohiro ^{[1
]}

Miyazaki, Masayoshi ^{[1
]}

Matsunaga, Takashi ^{[3
]}

Kumagai, Toru ^{[2
]}

Teshima, Teruki ^{[1
]}

机构：

[1] Osaka Int Canc Inst, Dept Radiat Oncol, Osaka, Japan

[2] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan

[3] Osaka Int Canc Inst, Dept Med Informat, Osaka, Japan

[4] Osaka Univ, Dept Radiat Oncol, Grad Sch Med, Osaka, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 12期

关键词：

Volumetric modulated arc therapy (VMAT); intensity modulated radiation therapy (IMRT); involved field radiotherapy irradiation (IFR-IFI); twice-daily thoracic radiotherapy (BID-TRT); accelerated hyperfractionated thoracic radiotherapy (AHTRT); anti-programmed cell death ligand-1 immune checkpoint inhibitor (ICIs); CONCURRENT CHEMOTHERAPY; STAGE IIIA; RADIATION; RADIOTHERAPY; SURVIVAL; COPD;

D O I：

10.21873/anticanres.14720

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The aim of this retrospective study was to detect the frequency, reasons, and significant factors for not receiving immunotherapy after chemoradiotherapy in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Thirty-four patients with NSCLC received definitive chemoradiotherapy. The endpoint of this study was receiving durvalumab within 45 days after chemoradiotherapy for NSCLC. Results: Twenty-five of 34 (73%) patients received immunotherapy within 45 days after chemoradiotherapy. The reasons for not receiving immunotherapy were radiation pneumonitis (50%), radiation esophagitis (10%), and four other reasons (40%). Univariate analysis showed that significant factors for not receiving immunotherapy were elective nodal irradiation (ENI)+ and chronic obstructive pulmonary disease (COPD)+. The rate of immunotherapy was 100% (17/17 cases) in the COPD- and ENI- group, and 16% (1/6 cases) in the COPD+ and ENI+ group. Conclusion: ENI for NSCLC complicated with COPD decreased the rate of immunotherapy after definitive chemoradiotherapy.

引用

页码：6957 / 6970

页数：14

共 50 条

[21] Clinical characteristics and gene mutation profiles of chronic obstructive pulmonary disease in non-small cell lung cancer
Yuan, Lin
Guo, Ting
Hu, Chengping
Yang, Wei
Tang, Xiaoli
Cheng, Hao
Xiang, Yang
Qu, Xiangping
Liu, Huijun
Qin, Xiaoqun
Qin, Ling
Liu, Chi
FRONTIERS IN ONCOLOGY, 2022, 12
[22] The prognosis of non-small cell lung cancer combined with chronic obstructive pulmonary disease: A systematic review and meta-analysis
Wu, Ke
Wang, Jing
Zhao, Limin
Wang, Pei
Duan, Qi
CLINICAL RESPIRATORY JOURNAL, 2020, 14 (04) : 389 - 396
[23] Magnetic resonance imaging biomarkers of chronic obstructive pulmonary disease prior to radiation therapy for non-small cell lung cancer
Sheikh, Khadija
Capaldi, Dante P. I.
Hoover, Douglas A.
Palma, David A.
Yaremkoe, Brian P.
Parraga, Grace
EUROPEAN JOURNAL OF RADIOLOGY OPEN, 2015, 2 : 81 - 89
[24] Thoracoscopic minimally invasive surgery for non-small cell lung cancer in patients with chronic obstructive pulmonary disease
Cui, Fei
Liu, Jun
Shao, Wenlong
He, Jianxing
JOURNAL OF THORACIC DISEASE, 2013, 5 : S260 - S266
[25] Outcomes of lobectomy on pulmonary function for early stage non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD)
Wei, Sen
Chen, Feng
Liu, Renwang
Fu, Dianxun
Wang, Yanye
Zhang, Bo
Ren, Dian
Ren, Fan
Song, Zuoqing
Chen, Jun
Xu, Song
THORACIC CANCER, 2020, 11 (07) : 1784 - 1789
[26] Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Non-Small-Cell Lung Cancer
Lee, Seung Jun
Lee, Jinwoo
Park, Young Sik
Lee, Chang-Hoon
Lee, Sang-Min
Yim, Jae-Joon
Yoo, Chul-Gyu
Han, Sung Koo
Kim, Young Whan
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (06) : 812 - 817
[27] Are patients with chronic obstructive pulmonary disease at a greater risk for the development of autoimmune thyroiditis as an adverse event of immunotherapy in non-small cell lung cancer treatment?
Zecevic, Andrej
Blanka-Protic, Ana
Jandric, Aleksandar
Adzic-Vukicevic, Tatjana
PATHOLOGY & ONCOLOGY RESEARCH, 2025, 31
[28] Pulmonologist Involvement, Stage-Specific Treatment, and Survival in Adults with Non-Small Cell Lung Cancer and Chronic Obstructive Pulmonary Disease
Deepak, Janaki A.
Ng, Xinyi
Feliciano, Josephine
Mao, Li
Davidoff, Amy J.
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 (05) : 742 - 751
[29] Identification of non-small cell lung cancer with chronic obstructive pulmonary disease using clinical symptoms and routine examination: a retrospective study
Zhuan, Bing
Ma, Hong-Hong
Zhang, Bo-Chao
Li, Ping
Wang, Xi
Yuan, Qun
Yang, Zhao
Xie, Jun
FRONTIERS IN ONCOLOGY, 2023, 13
[30] Chronic Obstructive Pulmonary Disease in Stage I Non-small Cell Lung Cancer That Underwent Anatomic Resection: The Role of a Recurrence Promoter
Kuo, Chih-Hsi
Wu, Ching-Yang
Lee, Kang-Yun
Lin, Shu-Min
Chung, Fu-Tsai
Lo, Yu-Lun
Liu, Chien-Ying
Hsiung, Te-Chih
Yang, Cheng-Ta
Wu, Yi-Cheng
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2014, 11 (04) : 407 - 413

← 1 2 3 4 5 →